Tempus AI (TEM) Is Up 5.2% After Winning Major Role in ARPA-H Adaptive Cancer Program

Tempus AI was recently chosen by the U.S. Department of Health and Human Services’ ARPA-H agency to deliver testing and clinical research services for the ADAPT precision cancer therapy program, offering its AI-powered diagnostics and clinical trial management expertise to accelerate adaptive cancer treatments. This federal collaboration underscores Tempus AI’s increasing role in advancing personalized medicine by integrating large-scale, real-world clinical and molecular data with AI-driven insights for improved cancer care. We'll explore how Tempus AI’s ARPA-H partnership for adaptive cancer trials might influence analyst expectations around its healthcare data advantage.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 24 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

Tempus AI Investment Narrative Recap

For a shareholder in Tempus AI today, the big-picture thesis is simple: you have to believe that large-scale, AI-powered precision medicine will win out and Tempus AI’s data-driven platform can capture enough adoption to drive sustainable, profitable growth. The ARPA-H partnership is a positive validation of Tempus AI’s platform, but it does not fundamentally shift the most important short-term catalyst: gaining reimbursement and approval for profitable new assays, nor does it eliminate the biggest risk, which remains sustained pressure from competition and pricing in diagnostics and data.

Among recent announcements, the September FDA clearance of Tempus xR IVD stands out for its relevance. This approval boosts the company’s ability to commercialize its oncology diagnostics, a key prerequisite for revenue growth and future reimbursement, directly tying into the same product categories highlighted by the ARPA-H deal.

By contrast, investors should not overlook the ongoing risk that intensifying competition or price pressure in genomics...

Read the full narrative on Tempus AI (it's free!)

Tempus AI's narrative projects $2.1 billion in revenue and $295.0 million in earnings by 2028. This requires 29.7% yearly revenue growth and a $494.7 million earnings increase from -$199.7 million today.

Uncover how Tempus AI's forecasts yield a $74.82 fair value, a 22% downside to its current price.

Exploring Other PerspectivesTEM Community Fair Values as at Oct 2025

Simply Wall St Community members submitted 34 fair value estimates for Tempus AI ranging from US$16.72 to US$93.38 per share. Several see revenue growth potential as a driver, but acknowledge that competition in diagnostics could test the durability of Tempus AI’s market position. Consider a variety of these viewpoints for a fuller picture.

Story Continues

Explore 34 other fair value estimates on Tempus AI - why the stock might be worth less than half the current price!

Build Your Own Tempus AI Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

A great starting point for your Tempus AI research is our analysis highlighting 1 key reward and 2 important warning signs that could impact your investment decision. Our free Tempus AI research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Tempus AI's overall financial health at a glance.

Ready For A Different Approach?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

Find companies with promising cash flow potential yet trading below their fair value. Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave. Rare earth metals are the new gold rush. Find out which 35 stocks are leading the charge.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include TEM.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments